RWJ Health Connect | Patient PortalGo
  • 1-888-MD-RWJUH
  • YouTube

Meet Our Staff

Bruce G Haffty, MD, is the Chair of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and the Rutgers Robert Wood Johnson Medical School, where he has created a world-class department spanning clinical, biological, and physics sciences.  Dr Haffty has led, and completed practice changing national clinical trials, such the ACOSOG Z11 trial, and the ongoing Alliance trial of post-chemotherapy local-regional management.  He is also a fully funded and accomplished translational scientist who has published important works in high-impact journals such as the Lancet and Cancer Cell.  Dr. Haffty has served as the President of the American Radium Society, the President of the American Board of Radiology (the certifying body for practicing radiation oncologists), and the immediate past-President and current Chairman of the Board of the American Society of Radiation Oncology (or ASTRO), the definitive scientific body of radiation oncologists.  Only one other radiation oncologist has served as president of all 3 societies.  

Rahul R. Parikh, MD, is the Medical Director of the Laurie Proton Therapy Center at Robert Wood Johnson University Hospital. He is a Radiation Oncologist at the Rutgers Cancer Institute of New Jersey (CINJ) and Assistant Professor of Radiation Oncology at Rutgers Robert Wood Johnson Medical School (RWJMS). ). Prior to joining RWJ, in 2013, he was appointed as Director of Proton Beam Therapy for the Mount Sinai Health System, where he successfully integrated the use of proton therapy into the multidisciplinary oncology treatment programs within the cancer center. Dr. Parikh joined the department of Radiation Oncology at CINJ/RWJMS in 2015 and is one of the only radiation oncologists in the Metro region to have formal clinical and academic experience with treating patients with proton therapy. Dr. Parikh has co-authored numerous clinical and translational papers in the oncology literature with a focus on patient-reported outcomes, lymphoma/hematologic malignancies, pediatric cancers, and proton beam therapy. Dr. Parikh serves on committees of national oncology organizations such as the American Society for Radiation Oncology (ASTRO), International Lymphoma Radiation Oncology Group (ILROG), Particle Therapy Co-Operative Group (PTCOG), and American Radium Society (ARS). He is also a member of several co-operative groups including Radiation Therapy Oncology Group (RTOG), Proton Collaborative Group (PCG). Also, as an active member of the Children's Oncology Group (COG), he is the primary radiation oncologist for children requiring radiation therapy. Dr. Parikh is also an active peer reviewer and editorial board for several oncology focused journals, including the Journal of Clinical Oncology and International Journal of Radiation Oncology, Biology, and Physics.

Sharad Goyal, MD, MS, is an attending in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey (CINJ) and Rutgers Robert Wood Johnson Medical School (RWJMS).  Dr. Goyal treats breast cancer, central nervous system/brain tumors, and melanoma/skin cancers.  His research areas have included clinical breast cancer, breast cancer treatment techniques and clinical trial development, outcomes measures, identifying patients at risk for side effects of cancer treatment, and the life quality of cancer survivors.  Dr. Goyal serves on committees of national oncology organizations such as the American Society of Clinical Oncology committees, American Society for Therapeutic Radiation Oncology, the American College of Radiology serves as a reviewer for several oncology journals, including the prestigious International Journal of Radiation Oncology, Biology, Physics.

Sabin B. Motwani, MD is an attending radiation oncologist who holds a dual faculty appointment at the Rutgers Cancer Institute of New Jersey (CINJ) in New Brunswick and the Rutgers New Jersey Medical School in Newark, NJ.  Dr. Motwani received his M.D. from the University of California, Irvine School of Medicine.  He then received the Stephen and Joan Alexander Research Fellowship at MD Anderson Cancer Center and completed his residency at Robert Wood Johnson Medical School.  Dr. Motwani treats patients with central nervous system and genitourinary tumors requiring radiation therapy since 2011.  Dr. Motwani has served as the PI for all Radiation Therapy Oncology Group clinical trials opened at Newark since 2013 and is actively involved in opening all adult CNS clinical trials at CINJ.  He was recently voted as Educator of the Year in 2014 by the Association of Residents in Radiation Oncology.  Dr. Motwani’s current research interest is investigating radiation techniques to minimize neurocognitive changes that may occur with radiation therapy.

Shabbar F. Danish, MD, FAANS is the Chief of Neurosurgery at the Rutgers Cancer Institute.  Dr. Danish completed his training at the University of Pennsylvania in 2008 before joining the faculty.  He has completed fellowship training in stereotactic and functional neurosurgery and in radiosurgery.  He is the Director for the Robert Wood Johnson Gamma Knife Program, which is currently the busiest program in New Jersey. Dr. Danish is a member of numerous national organizations, and specifically is involved in the national effort to understand the role of MRI guided laser therapy for brain tumors.  Dr. Danish is an active lecturer on treatment for inoperable brain tumors, is director for the Rutgers training course on laser therapy, and has published numerous articles on the topic.

Dr. Richard Drachtman is a Professor of Pediatrics at Rutgers Robert Wood Johnson Medical School, and Clinical Section Chief and Medical Director of the Division of Pediatric Hematology-Oncology at Rutgers Cancer Institute of New Jersey.  Dr. Drachtman is the Principal Investigator for The Children’s Oncology Group at Rutgers Biomedical and Health Sciences (RBHS). Dr. Drachtman has been with Rutgers (formerly UMDNJ) since 1991 following the completion of a fellowship in Pediatric Hematology-Oncology at Mt. Sinai Medical Center in New York. Dr. Drachtman is also involved in many clinical oncology trials for children as a member of the Children’s Oncology Group including the Children’s Oncology Group’s Hodgkins Disease retrieval group. Dr. Drachtman is the Vice Chair of RBHS’s Institutional Review Board, New Brunswick, NJ and in 2014, was appointed as Vice Chair on the National Cancer Institute’s Pediatric Central IRB.